LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Aktien・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Geschlossen

BrancheGesundheitswesen

2.56 -9.22

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.56

Max

2.61

Schlüsselkennzahlen
By Trading Economics
Einkommen	4.1M -5.7M
Angestellte	34
EBITDA	3.1M -6.8M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+678.21% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	9. Juni 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-113M 276M
Vorheriger Eröffnungskurs	11.78
Vorheriger Schlusskurs	2.56

Nachrichtenstimmung

By Acuity

50%

155 / 344 Ranking in Healthcare

Anavex Life Sciences Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Juni 2026, 19:20 UTC

Wichtige Markttreiber

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5. Juni 2026, 21:27 UTC

Ergebnisse

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5. Juni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5. Juni 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5. Juni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5. Juni 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5. Juni 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5. Juni 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5. Juni 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5. Juni 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5. Juni 2026, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5. Juni 2026, 17:50 UTC

Ergebnisse

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5. Juni 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5. Juni 2026, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. Juni 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5. Juni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2026, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. Juni 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5. Juni 2026, 15:25 UTC

Ergebnisse

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5. Juni 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Juni 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5. Juni 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5. Juni 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5. Juni 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer-Vergleich

Kursveränderung

Anavex Life Sciences Corp Prognose

Kursziel

By TipRanks

678.21% Vorteil

12-Monats-Prognose

Durchschnitt 20 USD 678.21%

Hoch 20 USD

Tief 20 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Anavex Life Sciences Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Anavex Life Sciences Corp – Dist abgegeben haben.

Stimmung

By Acuity

155 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.